Fortress Biotech, Inc.
Moat Score — Fortress Biotech, Inc.
Total Moat Score
9 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 3 / 5 | Fortress's value rests on licensed and acquired IP across its subsidiaries — UNLOXCYT's approved label, Journey Medical's branded dermatology portfolio, CUTX-101's orphan-disease positioning — but each asset's protection is tied to underlying patents and regulatory exclusivity it does not uniquely control, and much of the IP was in-licensed rather than internally invented. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 1 / 5 | Fortress is not a low-cost operator; its holding-company structure and reliance on recurring equity financing to fund multiple subsidiaries simultaneously is capital-intensive rather than cost-efficient relative to peers. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 2 / 5 | Journey Medical's branded dermatology products and Checkpoint's UNLOXCYT carry some price-setting ability typical of specialty pharma, but both face generic erosion risk and a fragmented, competitive dermatology/oncology market that limits durable pricing power. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | Fortress's licensing and drug-development business has no network effect — the value of any one subsidiary's product does not increase as more patients, physicians, or partners use it. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 1 / 5 | Once a drug is prescribed and a patient stabilized, there is modest physician and patient inertia, but this is weak relative to true switching costs, and most Fortress products ultimately face generic or branded substitution pressure. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 2 / 5 | Fortress's niche as a biotech incubator sourcing from elite academic cancer centers is a real structural advantage shared by relatively few comparable holding companies, but the broader biopharma licensing and development market itself is not capacity-constrained and remains open to well-funded competitors. |